VolumeVol. 54 • Number No. 4 • October - December 2016 Back
Clinical Trials
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0
International License, which permits use, share — copy and redistribute the material in any medium or format,
adapt — remix, transform, and build upon the material, as long as you give appropriate credit,
provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner,
but not in any way that suggests the licensor endorses you or your use. You may not use the material for
commercial purposes. If you remix, transform, or build upon the material, you must distribute your
contributions under the same license as the original. You may not apply legal terms or technological
measures that legally restrict others from doing anything the license permits. The images or other
third party material in this article are included in the article’s Creative Commons license, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons
license and your intended use is not permitted by statutory regulation or exceeds the permitted use,
you will need to obtain permission directly from the copyright holder. To view a copy of this license,
visit https://creativecommons.org/licenses/by-nc-sa/4.0/.
Effectiveness, Safety and Tolerability of Vildagliptin and Vildagliptin+Metformin in Real-world Setting in the Philippines—Results from the GUARD Study
Authors: Reynaldo Rosales, Francis Domingo, Joselito Javier
DOI: 10.65564/pjim.5f452c0142
Date of Publication: December 2016
More Details
Authors and Affiliations:
Reynaldo Rosales,M.D.*; Francis Domingo,M.D.* and Joselito Javier, M.D.**
*St. Luke’s Medical Center, Quezon City, Philippines;
**Novartis Healthcare Philippines Inc., Makati City, Philippines (current affiliation, GlaxoSmithKline Philippines)
Corresponding Author: Reynaldo Rosales, M.D., St. Luke’s Medical Center, Queon City, Philippines
Email address: [email protected]
License
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0
International License, which permits use, share — copy and redistribute the material in any medium or format,
adapt — remix, transform, and build upon the material, as long as you give appropriate credit,
provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner,
but not in any way that suggests the licensor endorses you or your use. You may not use the material for
commercial purposes. If you remix, transform, or build upon the material, you must distribute your
contributions under the same license as the original. You may not apply legal terms or technological
measures that legally restrict others from doing anything the license permits. The images or other
third party material in this article are included in the article’s Creative Commons license, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons
license and your intended use is not permitted by statutory regulation or exceeds the permitted use,
you will need to obtain permission directly from the copyright holder. To view a copy of this license,
visit https://creativecommons.org/licenses/by-nc-sa/4.0/.